Emerging Therapies in Erectile Dysfunction
This meeting took place on Wednesday 13th October 1999 at the Royal Society of Medicine.
The agenda was:
Viagra
Safety and Efficacy
Dr
Dale Glasser - Senior
Associate Director,
Safety Evaluation & Epidemiology,
Pfizer, USA
Clinical Experience with Viagra in the UK - one
year of personal clinical experience
Dr David Milledge - General Practitioner,
Coleshill, Birmingham, UK
International Community survey of erectile
dysfunction
Mr Philip Powell - Consultant Urologist,
Newcastle, UK
Apomorphine SL - a new oral therapy for erectile
dysfunction
Prof Jeremy Heaton - Department of Urology,
Queen's University,
Kingston, Ontario, Canada
EDiPC: Outcomes of a national training programme on erectile
dysfunction for General Practitioners
Dr John Dean - General Practitioner and Medical
Sexologist,
London & Plymouth, UK
Meeting the need for General Practitioner training in the
management of erectile dysfunction
Ms Edna Astbury-Ward - Urology Nurse Specialist, Rhyl, UK
The financial burden of erectile dysfunction
Mr Philip Powell - Consultant Urologist,
Newcastle, UK
Emerging Therapies in the treatment of erectile
dysfunction
Prof Jeremy Heaton - Department of Urology,
Queen's University,
Kingston, Ontario, Canada